Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Eli Lilly and Company (NYSE:LLY) stock is trading lower on Thursday after Viking Therapeutics, Inc. (NASDAQ:VKTX) announced the advancement of its novel treatment for obesity, VK2735.
週四維京療法公司（NASDAQ:VKTX）宣佈其對肥胖症的新型治療VK2735的進展，使Eli Lilly and Company（NYSE:LLY）股票交易走低。
The Details: Viking is advancing the injectable form of VK2735 to Phase 3 after receiving written feedback from an FDA Type C meeting. Also, the Phase 2 venture study of the drug yielded promising results.
詳情：在接到FDA C類會議的書面反饋後，維京公司將VK2735注射劑推進到III期。此外，該藥物的II期創業公司研究取得了有希望的結果。
VK2735 demonstrated an approximately 15% reduction in body weight from baseline following 13 weeks of treatment. The company anticipates scheduling an end-of-Phase 2 meeting with the FDA later this year.
在13周的治療後，VK2735顯示減輕基線體重約百分之15. 該公司預計今年晚些時候安排與FDA的II期結束會議（end-of-phase 2 meeting）的會議。
In addition, the Phase 1 study for the oral formulation of VK2735 demonstrated positive results. Participants reported a mean weight loss of up to 5.3% from baseline following 28 days of daily oral dosing. The company expects to start a Phase 2 study of this formulation during the fourth quarter of 2024.
此外，VK2735口服制劑的I期研究顯示出積極成果。參與者報告稱，他們在28天的每日口服劑量下與基線相比平均減重達到5.3％。該公司預計在2024年第四季度開始對該製劑進行II期研究。
Both forms of the new pharmaceutical appeared to be safe and well tolerated.
這兩種新藥物似乎都是安全和耐受性良好的。
Related Link: Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
相關鏈接：賽諾菲安萬特（Sanofi）在強勁的第二季度收益和拳頭產品Dupixent需求強勁的推動下，提高了2024年的利潤預測。
LLY Price Action: As of Thursday morning, Eli Lilly shares are trading 4.19% lower at $823.87 per data from Benzinga Pro.
LLY價格行情：根據Benzinga Pro的數據，截至週四上午，Eli Lilly（麗 Lilly）股票以每股823.87美元的價格交易，下跌了4.19％。
Image: Photo by rafapress on Shutterstock
圖片：來自Shutterstock的rafapress攝影
譯文內容由第三人軟體翻譯。